A comparison trial of Gallium-68-DOTATOC and Indium-111-pentetreotide in patients with MEN1 duodenal and pancreatic neuroendocrine tumors.

Trial Profile

A comparison trial of Gallium-68-DOTATOC and Indium-111-pentetreotide in patients with MEN1 duodenal and pancreatic neuroendocrine tumors.

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Gallium 68-DOTATOC (Primary) ; Indium-111-pentetreotide (Primary)
  • Indications Duodenal cancer; Neuroendocrine tumours; Pancreatic cancer
  • Focus Diagnostic use
  • Most Recent Events

    • 22 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top